JF
LCTX icon

Jump Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

Jump Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-36,120
Closed -$57.1K – 2270
2026
Q1 		$57.1K Buy
+36,120
New +$60.9K ﹤0.01% 1782
2025
Q3 		– Sell
-31,060
Closed -$28.2K – 2030
2025
Q2 		$28.2K Buy
+31,060
New +$18.4K ﹤0.01% 1725
2024
Q2 		– Sell
-72,849
Closed -$108K – 2053
2024
Q1 		$108K Buy
+72,849
New +$82.6K ﹤0.01% 1781

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jump Financial's LCTX Position: Q2 2026 in Review

Jump Financial sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 36,120 shares — an estimated $57.1K sold.

Jump Financial first reported a position in LCTX in Q1 2024 and held it in 3 quarters. The position peaked at $108K in Q1 2024. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Jump Financial reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jump Financial sold 36,120 Lineage Cell Therapeutics shares in Q2 2026, an estimated $57.1K.
  • Jump Financial first reported a position in Lineage Cell Therapeutics in Q1 2024 and held it in 3 quarters.
  • Jump Financial's Lineage Cell Therapeutics position peaked at $108K in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.